About Amicus Therapeutics
Amicus Therapeutics is a company based in Philadelphia (United States) founded in 2002 was acquired by BioMarin Pharmaceutical in December 2025. Amicus Therapeutics has raised $91 million across 13 funding rounds from investors including BioMarin Pharmaceutical, Blackstone and Frazier Healthcare Partners. The company has 499 employees as of December 31, 2024. Amicus Therapeutics has completed 2 acquisitions, including Callidus Biopharma and Scioderm. Amicus Therapeutics operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
- Headquarter Philadelphia, United States
- Employees 499 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Amicus Therapeutics, Inc.
-
Annual Revenue
$528.29 M (USD)32.29as on Dec 31, 2024
-
Net Profit
-$56.11 M (USD)62.99as on Dec 31, 2024
-
EBITDA
$42.61 M (USD)164.93as on Dec 31, 2024
-
Total Equity Funding
$91 M (USD)
in 13 rounds
-
Latest Funding Round
$30 M (USD), Post-IPO
Oct 02, 2023
-
Investors
BioMarin Pharmaceutical
& 10 more
-
Employee Count
499
as on Dec 31, 2024
-
Investments & Acquisitions
Callidus Biopharma
& 1 more
-
Acquired by
BioMarin Pharmaceutical
(Dec 19, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Amicus Therapeutics
Amicus Therapeutics is a publicly listed company on the NASDAQ with ticker symbol FOLD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Amicus Therapeutics
Unlock access to complete
Unlock access to complete
Leadership Team
50 people
Software Development Team
38 people
Legal and Compliance
11 people
Human Resources and Administration
9 people
Senior Team
9 people
Sales and Marketing
9 people
Operations Team
6 people
Product Management Team
4 people
Unlock access to complete
Funding Insights of Amicus Therapeutics
Amicus Therapeutics has successfully raised a total of $91M across 13 strategic funding rounds. The most recent funding activity was a Post-IPO round of $30 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Amicus Therapeutics
Amicus Therapeutics has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include BioMarin Pharmaceutical, Blackstone and Frazier Healthcare Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diversified investment management is provided across multiple asset classes.
|
Locked | Locked | Locked | |
|
Life sciences focused VC firm funding companies in the US and Europe
|
Locked | Locked | Locked | |
|
Canaan is recognized as an early-stage venture capital firm.
|
Locked | Locked | Locked |
Investor details for Amicus Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Amicus Therapeutics
Amicus Therapeutics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Callidus Biopharma and Scioderm.
Investment portfolio details for Amicus Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Topical therapies are developed for chronic skin diseases treatment.
|
Locked | Locked | 2012 | Locked | |
|
Enzyme replacement therapies (ERTs) for lysosomal storage disorders (LSDs)
|
Locked | Locked | 2010 | Locked |
Complete acquisition details for Amicus Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Amicus Therapeutics
Detailed financials for Amicus Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Amicus Therapeutics Comparisons
Peer comparison for Amicus Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Amicus Therapeutics
Amicus Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
Detailed competitors of Amicus Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Amicus Therapeutics
Complete news archive for Amicus Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Amicus Therapeutics
Amicus Therapeutics was founded in 2002.
Amicus Therapeutics is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Bradley L Campbell is the current CEO of Amicus Therapeutics.
Amicus Therapeutics is a funded company, having raised a total of $91M across 13 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Amicus Therapeutics is 499.
Annual revenue of Amicus Therapeutics is $528.29M as on Dec 31, 2024.
Amicus Therapeutics was founded in 2002 and is headquartered in Philadelphia, United States. Operations center on the biotechnology sector, where small-molecule therapies for rare and orphan diseases are advanced. A pipeline of pharmacological chaperones targets lysosomal storage disorders such as Fabry, Pompe, and Gaucher diseases. Key candidates include migalastat, an oral treatment for Fabry disease, and SD-101 for the genetic disorder Epidermolysis Bullosa.
Amicus Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Yes, Amicus Therapeutics is publicly traded on NASDAQ under the ticker symbol FOLD.
Amicus Therapeutics has made 2 acquisitions, including Callidus Biopharma, and Scioderm.
Amicus Therapeutics has 11 investors. Key investors include BioMarin Pharmaceutical, Blackstone, Frazier Healthcare Partners, Canaan, and The Michael J. Fox Foundation.
The ticker symbol of Amicus Therapeutics is FOLD on NASDAQ.